A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines

NCT00110305 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

368

Enrollment

INDUSTRY

Sponsor class

Conditions

Human Immunodeficiency Virus Type 1

Interventions

DRUG: TMC278 25 mg
DRUG: TMC278 75 mg
DRUG: TMC278 150 mg
DRUG: Efavirenz
DRUG: Non-nucleoside reverse transcriptase inhibitor (NRTIs)

Sponsor

Tibotec Pharmaceuticals, Ireland